From early detection to residual disease monitoring, these startups are developing liquid biopsy tests that could transform the way cancer is managed.
Liquid biopsy blood tests are gaining traction across the spectrum of care.
Advancements in genetic sequencing, microfluidics, and AI technology, coupled with greater understanding of disease-related biomarkers, have made liquid biopsies — which are far less invasive and more comprehensive than tissue biopsies — more precise and more sensitive than ever.
In the oncology space, liquid biopsies are already being used to guide treatments, monitor disease progression, and confirm preliminary diagnoses.
Now, thanks to improved sensitivity and specificity, they may be used to screen for early signs of disease in asymptomatic patients — which could have enormous implications for both patients and healthcare providers.
Want the full expert post? Become a CB Insights customer.
If you’re already a customer, log in here.